Skip to content

Study · Animal study (in vivo) · mouse · 2006

16 results

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV

Breast cancer research and treatment16 Mar 2006Cited by 79 (Europe PMC)

PMID16541323 (opens in a new tab)DOI10.1007/s10549-006-9168-1 (opens in a new tab)PepBankPUB-16541323
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In mice, intraperitoneal pegvisomant suppressed hepatic IGF-I mRNA by 60%.

    In plain wordsIn mice, injected pegvisomant reduced liver IGF-I gene activity by 60%.

    Peptide
    Pegvisomant
    Outcome
    DecreaseHepatic IGF-I mRNA
    Study

    mousen: not reported in source

    Mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Measurements

    Suppression
    60%
    hepatic IGF-I mRNA

    Source sentences

    Summary
    Intraperitoneal administration of pegvisomant resulted in a 60% suppression of hepatic IGF-I mRNA levels and upto a 70-80% reduction of serum IGF-I levels.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, intraperitoneal pegvisomant reduced serum IGF-I by up to 70-80%.

    In plain wordsIn mice, injected pegvisomant reduced blood IGF-I by up to 70-80%.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF-I
    Study

    mousen: not reported in source

    Mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Measurements

    Reduction
    70 to 80%
    up to

    Source sentences

    Summary
    Intraperitoneal administration of pegvisomant resulted in a 60% suppression of hepatic IGF-I mRNA levels and upto a 70-80% reduction of serum IGF-I levels.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In virgin female mice, pegvisomant significantly delayed mammary ductal outgrowth.

    In plain wordsIn female mice, pegvisomant delayed mammary duct growth.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMammary ductal outgrowth
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Mammary Development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In virgin female mice, pegvisomant-associated delayed ductal outgrowth accompanied fewer terminal end buds.

    In plain wordsIn female mice, pegvisomant treatment accompanied fewer terminal end buds in mammary glands.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTerminal end bud number
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Mammary Development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In virgin female mice, pegvisomant reduced mammary gland branching.

    In plain wordsIn female mice, pegvisomant reduced mammary gland branching.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMammary gland branching
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Mammary Development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In virgin female mice, pegvisomant reduced mammary gland complexity.

    In plain wordsIn female mice, pegvisomant reduced mammary gland complexity.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMammary gland complexity
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Mammary Development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, pegvisomant completely inhibited GH-mediated signaling in the mammary gland.

    In plain wordsIn mice, pegvisomant blocked GH signaling in mammary glands.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMammary GH signaling
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This effect of pegvisomant was mediated by a complete inhibition of both GH and IGF-IR-mediated signaling within the gland.
    2 context sentences
    Summary · context
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, pegvisomant completely inhibited IGF-IR-mediated signaling in the mammary gland.

    In plain wordsIn mice, pegvisomant blocked IGF-IR signaling in mammary glands.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMammary IGF-IR signaling
    Study

    mousen: not reported in source

    Virgin female mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This effect of pegvisomant was mediated by a complete inhibition of both GH and IGF-IR-mediated signaling within the gland.
    2 context sentences
    Summary · context
    Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland.
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MCF-7 xenografts, pegvisomant produced an initial 30% reduction in tumor volume.

    In plain wordsIn mice with MCF-7 breast tumors, pegvisomant initially reduced tumor volume by 30%.

    Peptide
    Pegvisomant
    Outcome
    DecreaseInitial MCF-7 xenograft volume
    Study

    mousen: not reported in source

    MCF-7 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Tumor volume reduction
    30%
    initial MCF-7 response

    Source sentences

    Summary
    In breast cancer xenograft studies, pegvisomant caused shrinkage of MCF-7 xenografts, with an initial 30% reduction in tumor volume, which was associated with a 2-fold reduction in proliferation and a 2-fold induction of apoptosis.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with MCF-7 xenografts, pegvisomant-associated regression accompanied a 2-fold reduction in proliferation.

    In plain wordsIn mice with MCF-7 tumors, pegvisomant treatment accompanied a 2-fold reduction in tumor cell multiplication.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMCF-7 proliferation
    Study

    mousen: not reported in source

    MCF-7 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Proliferation reduction
    2 fold
    MCF-7 xenografts

    Source sentences

    Summary
    In breast cancer xenograft studies, pegvisomant caused shrinkage of MCF-7 xenografts, with an initial 30% reduction in tumor volume, which was associated with a 2-fold reduction in proliferation and a 2-fold induction of apoptosis.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In mice with MCF-7 xenografts, pegvisomant-associated regression accompanied a 2-fold induction of apoptosis.

    In plain wordsIn mice with MCF-7 tumors, pegvisomant treatment accompanied a 2-fold increase in programmed cell death.

    Peptide
    Pegvisomant
    Outcome
    IncreaseMCF-7 apoptosis
    Study

    mousen: not reported in source

    MCF-7 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Apoptosis induction
    2 fold
    MCF-7 xenografts

    Source sentences

    Summary
    In breast cancer xenograft studies, pegvisomant caused shrinkage of MCF-7 xenografts, with an initial 30% reduction in tumor volume, which was associated with a 2-fold reduction in proliferation and a 2-fold induction of apoptosis.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MCF-7 xenografts, pegvisomant inhibited long-term tumor growth.

    In plain wordsIn mice with MCF-7 tumors, pegvisomant inhibited long-term tumor growth.

    Peptide
    Pegvisomant
    Outcome
    DecreaseLong-term MCF-7 xenograft growth
    Study

    mousen: not reported in source

    MCF-7 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Long-term growth inhibition of MCF-7 xenografts was noted.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MDA-231 xenografts, pegvisomant had no reported effect on tumor growth.

    In plain wordsIn mice with MDA-231 tumors, pegvisomant had no reported effect on tumor growth.

    Peptide
    Pegvisomant
    Outcome
    No significant changeMDA-231 xenograft response
    Study

    mousen: not reported in source

    MDA-231 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pegvisomant had no effect on MDA-231 or MDA-435 xenografts, consistent with primary growth of these xenografts being unresponsive to IGF-I both in vitro and in vivo.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In mice with MDA-435 xenografts, pegvisomant had no reported effect on tumor growth.

    In plain wordsIn mice with MDA-435 tumors, pegvisomant had no reported effect on tumor growth.

    Peptide
    Pegvisomant
    Outcome
    No significant changeMDA-435 xenograft response
    Study

    mousen: not reported in source

    MDA-435 breast cancer xenografts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pegvisomant had no effect on MDA-231 or MDA-435 xenografts, consistent with primary growth of these xenografts being unresponsive to IGF-I both in vitro and in vivo.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In regressed MCF-7 xenografts, pegvisomant had only minor effects on GHR signaling.

    In plain wordsIn mice with regressed MCF-7 tumors, pegvisomant had only minor effects on GHR signaling.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedGHR signaling in regressed MCF-7 xenografts
    Study

    mousen: not reported in source

    Regressed MCF-7 xenografts
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In MCF-7 xenografts that regressed, pegvisomant had only minor effects upon GHR and IGF-IR signaling.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In regressed MCF-7 xenografts, pegvisomant had only minor effects on IGF-IR signaling.

    In plain wordsIn mice with regressed MCF-7 tumors, pegvisomant had only minor effects on IGF-IR signaling.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedIGF-IR signaling in regressed MCF-7 xenografts
    Study

    mousen: not reported in source

    Regressed MCF-7 xenografts
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In MCF-7 xenografts that regressed, pegvisomant had only minor effects upon GHR and IGF-IR signaling.
    1 context sentence
    Summary · context
    In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.